Skip to contentE
Exousia Bio, Inc.
E
LMMYExousia Bio, Inc. Q1 2026 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2025 Net Income-$31.81K-$31.81KN/M vs Q1 2025 EPS Diluted$0.00$0.00— vs Q1 2025 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Exousia Bio, Inc. · CIK 1939937 · Engraved from SEC EDGAR
Operating Cash Flow$3,500N/M ended Aug 31, 2025 · filed Nov 17, 2025 · 78 d after period end